NCT05661188 — Grupo Espanol Multidisciplinario del Cancer… cancer immunotherapy trial
Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)
Registry record
| Registry ID | NCT05661188 ↗ |
|---|---|
| Lead sponsor | Grupo Espanol Multidisciplinario del Cancer Digestivo |
| Collaborators | Hoffmann-La Roche |
| Phase | Phase 2 |
| Status | Completed |
| Indication | Squamous Cell Carcinoma of the Anal Canal |
| Enrollment | 45 participants |
| Start date | 2023-02-14 |
| Primary completion | 2026-09-25 |
| Last registry update | 7 Oct 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05661188), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
FAQ
What phase is NCT05661188?
NCT05661188 (Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)) is registered on ClinicalTrials.gov as Phase 2, sponsored by Grupo Espanol Multidisciplinario del Cancer Digestivo.
Is NCT05661188 recruiting?
As of the 2026-10-07 registry update, NCT05661188 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05661188?
The lead sponsor is Grupo Espanol Multidisciplinario del Cancer Digestivo. Collaborators: Hoffmann-La Roche.
What condition does NCT05661188 study?
The registered condition is Squamous Cell Carcinoma of the Anal Canal. Primary completion is listed as 2026-09-25.
Are results available for NCT05661188?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05661188.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.